Bispecific Antibodies Market

Bispecific Antibodies Market - Size, Share,
Growth, Outlook, and Opportunity Analysis,
2018-2026
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different
monoclonal antibodies and has ability to bind to two different types of antigen. Cancer
immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon
cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic
cell and target tumor cell and destroys it. Bispecific antibodies are emerging a technologically
advanced solution for dual targeting strategies within same molecule.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/19
Due to its dual specificity, bispecific antibody can aid in redirecting T cells to tumor cells, blocking two
different signaling pathways simultaneously, dual targeting of different disease mediators, and
delivering payloads to targeted sites. Catumaxomab and blinatumomab are the two U.S. FDA
approved bispecific antibody products, which would fuel growth of the bispecific antibodies market.
Bispecific antibodies can be divided into three main classes namely, fragment, symmetric, and
asymmetric antibodies. Fragment bispecific antibodies such as a nanobody DART and BiTE are
currently undergoing clinical trials. Likewise, tetravalent BsAb - DVD and DAF symmetric antibodies
are under research. Companies such as Sanofi S.A., Merck & Co., Inc. and Genentech, Inc. are
conducting research on symmetric bispecific antibodies. BEAT, duobody, and crossmab are
examples of asymmetric bispecific antibodies, which are currently being researched by Glenmark
Pharmaceuticals, Eli Lilly and Company, and Genmab A/S.
Catumaxomab – the first Bispecific antibody boost growth of the bispecific antibodies
market
As of 2015, over 60 different BsAb formats have been developed, with some making their way
into the clinical trials. Bispecific antibodies market growth is increasing due to the limitation of
monoclonal antibodies in drug resistance and failure to respond in treatment. Hence, the
bispecific antibodies market is projected to gain significant growth traction in the near future.
Catumaxomab is a rat – mouse hybrid monoclonal bispecific trifunctional antibody used to treat
malignant ascites. It was developed by Fresenius Biotech and Trion Pharma. Catumaxomab was
approved in Europe in 2009 and is undergoing clinical trials in the U.S. Sold under the brand
name Removab, Catumaxomab is administered to patients with EpCAM-poisitve carcinoma.
Report includes chapters which deeply display the following deliverable about industry :
• Bispecific Antibodies Market Research Objective and Assumption
• Bispecific Antibodies Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Bispecific Antibodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Bispecific Antibodies Market, By Regions
• Bispecific Antibodies Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Bispecific Antibodies Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Bispecific Antibodies Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Bispecific Antibodies Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key players involved in the bispecific antibodies market include
Some of the key players in Bispecific antibodies market are Amgen, Inc., Bayer AG,
Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co.,
Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG.
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/19
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Download Report